The short version of regulatory status fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-08-01. Anything still debated is marked as such rather than presented as settled.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Status varies by country; prohibited in sport. |
| Common storage temperature | 2–8 °C for lyophilized powder | Protect from light and moisture; follow supplier instructions. |
| Typical analytical method | LC-MS/MS | Used for identification and quantification in biological samples. |
| Purity assessment | HPLC and mass spectrometry | Reverse-phase HPLC is common for peptide purity. |
| Common synonyms | AOD9604; hGH 176-191 fragment | Naming conventions differ across studies. |
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
=== Afrikaans === Afrikaans, as it is a daughter language of the Dutch language, is capable of forming compounds of potentially limitless length in the same way as in the Dutch language. According to the Total Book of South African Records, the longest word in the language is Tweedehandsemotorverkoopsmannevakbondstakingsvergaderingsameroeperstoespraakskrywerspersverklaringuitreikingsmediakonferensieaankondiging (136 letters), which means "issuable media conference's announcement at a press release regarding the convener's speech at a secondhand car dealership union's strike meeting". This word, however, is contrived to be long and does not occur in everyday speech or writing.
He quickly established a characteristic style, marked by slow, episodic and ambiguous narrative structures as well as long takes (The Travelling Players, for example, consists of only 80 shots in about four hours of film). These takes often include meticulously choreographed and complicated scenes involving many actors. His regular collaborators include the cinematographer Giorgos Arvanitis, the screenwriter Tonino Guerra and the composer Eleni Karaindrou. One of the recurring themes of his work is immigration, the flight from homeland and the return, as well as the history of 20th century Greece. Angelopoulos was considered by British film critics Derek Malcolm and David Thomson as one of the world's greatest directors. Famous film directors including Werner Herzog Emir Kusturica, Akira Kurosawa, Ingmar Bergman, Wim Wenders, Dušan Makavejev, William Friedkin, Manoel de Oliveira, and Michelangelo Antonioni, among others, were admirers of his works. While critics have speculated on how he developed his style, Angelopoulos made clear in one interview that "The only specific influences I acknowledge are Orson Welles for his use of plan-sequence and deep focus, and Mizoguchi, for his use of time and off-camera space." He had also cited Andrei Tarkovsky's 1979 work Stalker as an influence.
Humans do not produce cellulases, chitinases, or trehalases, but the bacteria in the gut microbiota do. In order to get into or out of cell membranes of cells and membranes of cell compartments, glucose requires special transport proteins from the major facilitator superfamily. In the small intestine (more precisely, in the jejunum), glucose is taken up into the intestinal epithelium with the help of glucose transporters via a secondary active transport mechanism called sodium ion-glucose symport via sodium/glucose cotransporter 1 (SGLT1). Further transfer occurs on the basolateral side of the intestinal epithelial cells via the glucose transporter GLUT2, as well uptake into liver cells, kidney cells, cells of the islets of Langerhans, neurons, astrocytes, and tanycytes. Glucose enters the liver via the portal vein and is stored there as a cellular glycogen. In the liver cell, it is phosphorylated by glucokinase at position 6 to form glucose 6-phosphate, which cannot leave the cell. Glucose 6-phosphatase can convert glucose 6-phosphate back into glucose exclusively in the liver, so the body can maintain a sufficient blood glucose concentration. In other cells, uptake happens by passive transport through one of the 14 GLUT proteins. In the other cell types, phosphorylation occurs through a hexokinase, whereupon glucose can no longer diffuse out of the cell. The glucose transporter GLUT1 is produced by most cell types and is of particular importance for nerve cells and pancreatic β-cells. GLUT3 is highly expressed in nerve cells.
== Treatments == Because different types of myopathies are caused by many different pathways, there is no single treatment for myopathy. Treatments range from treatment of the symptoms to very specific cause-targeting treatments. Drug therapy, physical therapy, bracing for support, surgery, and massage are all current treatments for a variety of myopathies.
Pyrimidine oxygenase (EC 1.14.99.46, gene RutA) is an enzyme characterised from Escherichia coli with systematic name uracil,FMNH2:oxygen oxidoreductase (uracil hydroxylating, ring-opening). It catalyses two related oxidation reactions which act on pyrimidine nucleobases. The overall effect of the first example is to convert uracil to (Z)-3-ureidoacrylic acid with molecular oxygen as the oxidant and flavin mononucleotide (FMN) as a cofactor. The enzyme also requires nicotinamide adenine dinucleotide (NADH):
Sources: en.wikipedia.org
== Treatment == There are many causes of necrosis, and as such treatment is based upon how the necrosis came about. Treatment of necrosis typically involves two distinct processes: Usually, the underlying cause of the necrosis must be treated before the dead tissue itself can be dealt with.
=== Classification === Classification of personality disorders differs significantly between the two most prominent frameworks for classification of mental disorders, namely: the Diagnostic and Statistical Manual of Mental Disorders and the International Classification of Diseases, the most recent editions of which are the DSM-5-TR and ICD-11, respectively. While personality disorders, including BPD, are diagnosed as separate entities in the DSM-5; in the ICD-11 classification of personality disorders, they are assessed in terms of severity levels, with trait and pattern specifiers serving to characterize the particular style of pathology. There is also a hybrid model, called the Alternative DSM-5 model for personality disorders, which defines BPD and five other PDs through disorder-specific combinations of pathological traits and areas of overall impairment.
As part of Operation Typhoon, the 4th Panzer Group was subordinated to the 4th Army under the command of Günther von Kluge. In early October, the 4th Panzer Group completed the encirclement at Vyazma. Kluge instructed Hoepner to pause the advance, much to the latter's displeasure, as his units were needed to prevent break-outs of Soviet forces. Hoepner was confident that the clearing of the pocket and the advance on Moscow could be undertaken at the same time and viewed Kluge's actions as interference, leading to friction and "clashes" with his superior, as he wrote in a letter home on 6 October. Hoepner did not seem to appreciate that his units were very short on fuel; the 11th Panzer Division, reported having no fuel at all. Only the 20th Panzer Division was advancing towards Moscow amid deteriorating road conditions. Once the Vyazma pocket was eliminated, other units were able to advance on 14 October. Heavy rains and onset of the rasputitsa (roadlessness) caused frequent damage to tracked vehicles and motor transport further hampering the advance. By early November, the 4th Panzer Group was depleted from earlier fighting and the weather but Hoepner, along with other panzer group commanders and Fedor von Bock, commander of Army Group Center, was impatient to resume the offensive. On 17 November, the 4th Panzer Group attacked again towards Moscow alongside the V Army Corps of the 4th Army, as part of the continuation of Operation Typhoon by Army Group Centre. The panzer group and the army corps represented Kluge's best forces, most ready for a continued offensive.
Metallothionein biosynthesis can also be induced by certain hormones, pharmaceuticals, alcohols, and other compounds. Metallothionein expression is upregulated during fetal development, particularly in liver tissue.
=== Energy sources === Kardashev's classification is based on the hypothesis that an advanced civilization uses significant energy, which implies that it must be de facto detectable over long distances, as summarized by Zoltan Galántai. For Kardashev, the limit of a civilization's energy consumption is originally located in the region of the electromagnetic spectrum from 106 to 108 Hz, which allows two observations related to thermodynamics. First, all the energy consumed is inevitably converted into heat. Second, this energy can only be dissipated in the form of radiation scattered in space. These two findings are the pillars of Kardashev's theory that cosmic objects with strong radiation could be artificial sources. He also considered the possibility of detecting an artificial source by emphasizing the spectral line of hydrogen in its use for nuclear fusion. Dutil and Dumas consider several physical limits to continuous energy production, such as photosynthesis (about 10 TW), climate (about 127 TW), and solar flux (174,000 TW). The only inexhaustible source of energy that can sustain a civilization for over several billion years, is deuterium (used in nuclear fusion). The sustainability of a civilization must therefore involve "strict control of the exploitation of available resources"; this difficulty in exceeding energy limits may explain the fact that the vast majority of civilizations fail to engage in a space colonization project.
Sources: en.wikipedia.org
=== Gawker === In May 2016, Ayyadurai filed suit against Gawker Media for $35 million, alleging that their website Gawker published "false and defamatory statements", causing "substantial damage to Dr. Ayyadurai's personal and professional reputation and career". The filing also named writer Sam Biddle, executive editor John Cook, and Gawker founder and CEO Nick Denton. Gawker Media responded that, "These claims to have invented email have been repeatedly debunked by the Smithsonian Institute [sic], Gizmodo, the Washington Post and others." In November 2016, the by-then-bankrupt Gawker Media settled the lawsuit with Ayyadurai for $750,000 as part of a broader settlement with wrestler Hulk Hogan and journalist Ashley Terrill, all of whom were represented by attorney Charles Harder. In a statement, Ayyadurai said that "history will reflect that this settlement is a victory for truth". Biddle denounced the settlement and said he fully stood by his reporting. Denton wrote that "we expected to prevail" in the Ayyadurai and Terrill lawsuits, "but all-out legal war with" billionaire Peter Thiel, who financially backed Harder, was untenable in terms of cost, time and human toll. Katie Hafner, the author of several books on Internet history—including one on the development of ARPANET email—said, "This situation is both bizarre and appalling in that here we are simply trying to get the record straight, and [Ayyadurai has] managed to make money off claims that appear to be misleading."
== Environment == Endolithic microorganisms have been reported in many areas around the globe. There are reports in warm hyper-arid and arid deserts such as Mojave and Sonora (USA), Atacama (Chile), Gobi (China, Mongolia), Negev (Israel), Namib (Namibia Angola), Al-Jafr basin (Jordan) and the Depression of Turpan (China), also in cold deserts as Arctic and Antarctic, and deep subsoil and ocean trenches rocks. However, there are reports of endolithic microorganisms in inter-tropical zones, where humidity and solar radiation are significantly different from the above-mentioned biomes. Endoliths have been found in the rock down to a depth of 3 km (1.9 mi), though it is unknown if that is their limit (due to the cost involved in drilling to such depths). The main threat to their survival seems not to result from the pressure at such depth, but from the increased temperature. Judging from hyperthermophile organisms, the temperature limit is at about 120 °C (Strain 121 can reproduce at 121 °C), which limits the possible depth to 4-4.5 km below the continental crust, and 7 or 7.5 km below the ocean floor. Endolithic organisms have also been found in surface rocks in regions of low humidity (hypolith) and low temperature (psychrophile), including the Dry Valleys and permafrost of Antarctica, the Alps, and the Rocky Mountains.
enzyme A protein which acts as a catalyst for a biological process by accelerating a specific chemical reaction, typically by binding one or more substrate molecules and decreasing the activation energy necessary for the initiation of a particular reaction involving the substrate(s). Enzymatic catalysis often results in the chemical conversion of the substrate(s) into one or more products, which then inhibit or permit subsequent reactions. All metabolic pathways consist of a series of individual reactions which each depend upon one or more specific enzymes to drive them forward at rates fast enough to sustain life.
=== Emergence of orphan diseases === In response to incidents such as difficulties with thalidomide the Kefauver-Harris Amendment was passed in 1962 as an amendment to the Federal Food, Drug, and Cosmetic Act. Kefauver-Harris required that all drugs approved for sale be proven safe and effective via rigorous scientific studies. While this legislation improved drug safety, it also dramatically increased the costs associated with developing new medicines. Pharmaceutical companies responded by focusing on developing treatments for common diseases in order to maximize the possibility of recouping research and development costs and generating significant profits. As a result, rare diseases were largely ignored due to poor economic potential and were thus said to be "orphaned." The gap between drugs for common versus rare diseases eventually widened to the point where few or no treatments were available for some rare conditions such as Crohn's disease, Hansen's disease, etc.
=== Animal models === Fetomaternal microchimerism has been shown in experimental investigations of whether fetal cells can cross the blood brain barrier in mice. The properties of these cells allow them to cross the blood brain barrier and target injured brain tissue. This mechanism is possible because umbilical cord blood cells express some proteins similar to neurons. When these umbilical cord blood cells are injected in rats with brain injury or stroke, they enter the brain and express certain nerve cell markers. Due to this process, fetal cells could enter the brain during pregnancy and become differentiated into neural cells. Fetal microchimerism can occur in the maternal mouse brain, responding to certain cues in the maternal body.
Sources: en.wikipedia.org
No major regulatory agency has approved AOD-9604 as a medicine. It is treated as an experimental peptide in research settings. Some countries restrict its sale or import.
The World Anti-Doping Agency classifies growth hormone fragments, including AOD-9604, as prohibited substances. The classification reflects concern about potential performance-enhancing use. Athletes are subject to testing for such peptides.
Detection typically uses liquid chromatography combined with mass spectrometry. These methods separate the peptide and identify it by mass. Immunoassays may screen samples but require confirmation by a more specific technique.
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.